Bristol Myers Squibb Stock: Bull vs. Bear
With a market cap of more than $125 billion, Bristol Myers Squibb (NYSE: BMY) is one of the healthcare sector's largest competitors, but don't interpret that to mean it isn't a dynamic company. Though its earnings are shrinking and it isn't profitable at the moment, its revenue continues to expand via a constant drumbeat of regulatory approvals to commercialize its drugs.
But will that be enough to counter the looming loss of exclusivity for several of its winning products in the next few years? Let's look at a pair of opposing arguments on the subject and find out.
Image source: Getty Images.
Source Fool.com
